Although pediatric GBM landscape is considered to be very different from the adult GBMs and the research is focused on finding different drugs for the two GBM types, we found that both pediatric low and high-grade gliomas expressed high levels of SUMO2 (Pediatric Brain Tumour Atlas: CBTTC from UCSC Xena) (Fig. 3D and Additional file 4: Table S32). Here, SUMO2 is linked to central nervous system cancer.